APR 23, 2018 5:00 AM PDT

UroSEEK: Early Bladder and Urothelial Cancer Urine Screening Test Developed to Complement Urine Cytology

WRITTEN BY: Mauri Brueggeman

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a new gene-based test to detect and monitor cancers involving the bladder and upper urothelial tissues.  They called it UroSEEK which is similar to CancerSEEK, also developed at Johns Hopkins to screen for 8 common cancer types with a single blood test.

UroSEEK information was released in late March 2018 and detects DNA mutations identified in bladder and upper tract urothelial cancers (BC and UTUC respectively).  Prior to this new developed test, urine cytology was the least invasive and standard screening tool but it had limitations.  Voided urine cytology examines cellular morphologic changes which occur in cancerous cells; laboratorians performing the analysis are looking for cellular clumping, high nuclear to cytoplasmic ratio, presence of nucleoli (indicating younger, less mature cells), and other atypical features indicating a potential disease process.  There are some reports that urine cytology can very accurately diagnose high grade carcinoma and bladder cancer in situ.

There are challenges to this standard test/screen option, including:

  • Employment and retention of skilled cytologists and cytopathologists to perform analysis

  • Low sensitivity due to tumor differences and tumor grade – high grade tumors with distinct and high degree of morphological change will be identified more accurately and more consistently; lower grade or early tumorigenesis (low grade BC and UTUCs) is difficult, if not impossible, to detect

  • Specimen quality and quantity

UroSEEK tests for DNA changes commonly associated with BC and UTUC, which can both present challenges for early diagnosis.  UroSEEK has three components and aims not to replace urine cytology but complement it to improve sensitivity and early disease detection.  The first, is to detect mutations in the regions of 10 genes consistently found to be mutated in urothelial tumors: FGFR3, TP53, CDKN2A, ERBB2, HRAS, KRAS, PIK3CA, MET, VHL, and MLL.  Some of these may sound familiar; they are involved in additional oncogenic pathways in other cancers across multiple tissues and locations.  The second component detects the mutation of an oncogenic promoter called TERT.  Lastly, the test acts to detect aneuploidy (presence of abnormal number of chromosomes in a cell).  These three factors are known to contribute to these types of cancers. 

The testing method involves the use of three separate assays.  Multiplex PCR for the first 10 gene analysis, singleplex PCR for the TERT promoter gene examination, and PCR to co-amplify L1 retrotransposon repeats, known as LINEs, which are known to be on all 39 acrocentric autosomal chromosome arms as published in 2012 in PLoS One

This approach is a valuable use of technology and diagnostic combination to help improve patient care and outcomes.  Questions to further consider will be the feasibility of offering this test in healthcare systems or institutions that don’t have large reference laboratory or molecular diagnostic lab capabilities.  In addition, from the provider and insurance perspective, often insurers will allow only certain approved standard testing for screening purposes.  How long will it take for agreement and policy changes to be implemented to allow for this type of testing to be “part” of the screening standard rather than a “compliment” which some may determine is not necessary.  This impacts the patient and billing practices of the laboratory and institution, which could greatly affect the likelihood of its use or implementation.

 

Sources: Elife Journal, Oncology Times, Medscape, PLos One,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
AUG 12, 2020
Cancer
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
AUG 12, 2020
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
Since the 1940s, chemotherapy has been a primary treatment option for cancer. The late 20th century brought a new type o ...
AUG 16, 2020
Cancer
Cancer mapping shows health disparities in remote areas
AUG 16, 2020
Cancer mapping shows health disparities in remote areas
Scientists mapping cancer statistics have developed a new mathematical model to track health inequalities relating to th ...
SEP 11, 2020
Cancer
Taking cancer treatment from a whole new angle
SEP 11, 2020
Taking cancer treatment from a whole new angle
New cancer research is looking at treatment for the disease from an entirely new angle: structurally. While chemotherapy ...
SEP 14, 2020
Cancer
We are too uneducated on the risks of colon cancer
SEP 14, 2020
We are too uneducated on the risks of colon cancer
A study conducted by researchers from Florida Atlantic University's Schmidt College of Medicine suggests that too ma ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
Loading Comments...